GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

First Posted Date: 2016-12-01

Last Posted Date: 2019-10-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 404

Registration Number: NCT02979639

Locations: 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States

Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain

Phase 4

Terminated

Conditions: Pain

Interventions: Other: Placebo
Drug: Paracetamol and caffeine
Drug: Paracetamol

First Posted Date: 2016-11-28

Last Posted Date: 2018-08-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 21

Registration Number: NCT02974114

Locations: 🇬🇧
GSK Investigational Site, Brentford, Middlesex, United Kingdom

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo ELLIPTA DPI
Drug: GSK2269557 ELLIPTA DPI

First Posted Date: 2016-11-25

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02972905

Locations: 🇯🇵
GSK Investigational Site, Fukuoka, Japan

A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

Phase 3

Completed

Conditions: Anaemia

Interventions: Drug: Daprodustat small
Drug: Daprodustat small placebo
Drug: Daprodustat large
Drug: Daprodustat large placebo
Drug: Darbepoetin alfa placebo
Drug: Darbepoetin alfa

First Posted Date: 2016-11-21

Last Posted Date: 2020-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 271

Registration Number: NCT02969655

Locations: 🇯🇵
GSK Investigational Site, Yamaguchi, Japan

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

Phase 2

Completed

Conditions: Cholestasis

Interventions: Drug: Placebo
Drug: GSK2330672

First Posted Date: 2016-11-17

Last Posted Date: 2021-05-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 147

Registration Number: NCT02966834

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: GSK3117391

First Posted Date: 2016-11-17

Last Posted Date: 2020-10-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3

Registration Number: NCT02965599

Locations: 🇷🇴
GSK Investigational Site, Targu Mures, Romania

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: GSK525762
Drug: Placebo
Drug: Fulvestrant

First Posted Date: 2016-11-16

Last Posted Date: 2024-08-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 124

Registration Number: NCT02964507

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV Vaccine (GSK3003891A) formulation 3
Biological: RSV Vaccine (GSK3003891A) formulation 1
Biological: RSV Vaccine (GSK3003891A) formulation 2
Drug: Placebo (Formulation buffer S9b)